Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AE37 + Pembrolizumab in mTNBC
NCT04024800Phase 2Unknown
- Sponsor
- NuGenerex Immuno-Oncology
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AE37 in triple-negative breast cancer (TNBC), sponsored by NuGenerex Immuno-Oncology. Status: unknown.
02
Drugs
AE37
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04024800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024800.